TIGIT and malignant colon neoplasm: Second, efficacy for ZGGS15 (only the anti-TIGIT part is active in this model) plus anti-PD-1 in the BALB/c-hPD-1/hTIGIT mouse bearing CT26 colon cancer model was performed.